Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856529 | 0.85 | KDM4E (0.39) | KCNH2CACNA1ISIGMAR1CARM1PRMT6 | |
| SCHEMBL16748041 | 0.81 | L3MBTL1 (0.43) | KCNH2CACNA1ICARM1PRMT6 | |
| SCHEMBL23560045 | 0.79 | EPHX1 (0.41) | KCNH2CACNA1ISIGMAR1 | |
| SCHEMBL27307514 | 0.79 | SIGMAR1 (0.33) | KCNH2CACNA1ISIGMAR1CARM1PRMT6 | |
| SCHEMBL23588513 | 0.79 | SAT1 (0.39) | KCNH2CACNA1ISLC6A3CARM1PRMT6 | |
| SCHEMBL17010888 | 0.77 | CACNA1I (0.40) | KCNH2CACNA1ISLC6A3 | |
| SCHEMBL23806826 | 0.76 | EPHX1 (0.43) | CARM1PRMT6 | |
| SCHEMBL27307544 | 0.76 | CARM1 (0.36) | SIGMAR1CARM1PRMT6 | |
| SCHEMBL8246654 | 0.76 | SLC6A3 (0.33) | SLC6A3 | |
| SCHEMBL25726118 | 0.75 | KCNH2 (0.32) | KCNH2CACNA1ISIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | KCNH2 4583/4885CACNA1I 4806/4885SLC6A3 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.